Axovant Sciences (NASDAQ: AXON) today announced that the Phase 3 MINDSET clinical trial of its investigational drug intepirdine in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trading Halts

Axovant Sciences (AXON) PT Lowered to $25 at Cowen; Lewy Body Program Remains FocusSeptember 26, 2017 11:48 AM UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to NeutralSeptember 26, 2017 10:53 AM Oppenheimer Downgrades Axovant Sciences (AXON) to PerformSeptember 26, 2017 10:48 AM UPDATE: Axovant Sciences (AXON) PT Lowered to $3 at Chardan Capital MarketsSeptember 26, 2017 9:49 AM Baird Downgrades Axovant Sciences (AXON) to Neutral, $6 PTSeptember 26, 2017 9:38 AM Axovant Sciences (AXON) Sinks 70% as Trading ResumesSeptember 26, 2017 7:32 AM Axovant Sciences (AXON) to Resume Trading at 7:30 AM ETSeptember 26, 2017 7:05 AM Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's DiseaseSeptember 26, 2017 7:00 AM Axovant Sciences (AXON) Halted, News PendingSeptember 26, 2017 6:58 AM